Paper published in a journal (Scientific congresses and symposiums)
Abstract 2993: Unmutated tumor antigens are abundant and contribute to tumor control in melanoma
Apavaloaei, Anca; Zhao, Qingchuan; Hesnard, Leslie et al.
2023In Cancer Research, 83 (7_Supplement), p. 2993-2993
Peer Reviewed verified by ORBi
 

Files


Full Text
Poster Presentations.pdf
Author postprint (192.03 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Cancer Research; Oncology
Abstract :
[en] Abstract Recognition of MHC-I-associated tumor antigens (TAs) by CD8+ T cells is central to antitumor immunity. Owing to the elevated tumor mutational burden (TMB) in melanoma, the marked efficacy of immune checkpoint blockade (ICB) has been attributed to the recognition of mutated TAs. However, recent reports showed that response to ICB in melanomas with low TMB is associated with CD8+ T-cell reactivity against melanocyte lineage-associated antigens (LSAs). Here, we systematically evaluated the contribution of all TA classes, i.e., mutated and unmutated, canonical and non-canonical, to the antigenic landscape of melanoma. We characterized the TAs from melanoma biopsies and patient-derived cell lines using proteogenomics. Out of 79450 MHC-I-associated peptides (MAPs) identified from 19 samples, we found 557 unmutated TAs classified as tumor-specific (TSA), tumor-associated (TAA), or LSAs. These TAs most often derived from annotated open-reading frames, followed by ncRNAs and intergenic regions. By contrast, only 6 MAPs were mutated and tumor-specific, which could be partially explained by a decreased expression of mutations within MAP-generating genomic regions. While the number of unmutated TAs with predicted presentation (TApres) in melanoma patients was similar between responders and non-responders pre-ICB, non-responders showed marks of inefficient antigen presentation. In consequence, only responders lost TApres upon treatment, in tandem with an expansion in tumor-infiltrating lymphocytes. These results reveal a previously underappreciated contribution of unmutated TAs to tumor control in melanoma and suggest that enhancing their recognition could improve the ICB efficacy in non-responders. Citation Format: Anca Apavaloaei, Qingchuan Zhao, Leslie Hesnard, Krystel Vincent, Marie-Pierre Hardy, Chantal Durette, Joël Lanoix, Jean-Philippe Laverdure, Jean-David Larouche, Maria Virginia Ruiz Cuevas, Grégory Ehx, Sébastien Lemieux, Pierre Thibault, Claude Perreault. Unmutated tumor antigens are abundant and contribute to tumor control in melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2993.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Apavaloaei, Anca;  1University of Montreal, Montreal, Quebec, Canada,
Zhao, Qingchuan;  1University of Montreal, Montreal, Quebec, Canada,
Hesnard, Leslie;  1University of Montreal, Montreal, Quebec, Canada,
Vincent, Krystel;  1University of Montreal, Montreal, Quebec, Canada,
Hardy, Marie-Pierre;  1University of Montreal, Montreal, Quebec, Canada,
Durette, Chantal;  1University of Montreal, Montreal, Quebec, Canada,
Lanoix, Joël;  1University of Montreal, Montreal, Quebec, Canada,
Laverdure, Jean-Philippe;  1University of Montreal, Montreal, Quebec, Canada,
Larouche, Jean-David;  1University of Montreal, Montreal, Quebec, Canada,
Cuevas, Maria Virginia Ruiz;  1University of Montreal, Montreal, Quebec, Canada,
Ehx, Grégory  ;  Université de Liège - ULiège > Département des sciences cliniques
Lemieux, Sébastien;  1University of Montreal, Montreal, Quebec, Canada,
Thibault, Pierre;  1University of Montreal, Montreal, Quebec, Canada,
Perreault, Claude;  1University of Montreal, Montreal, Quebec, Canada,
More authors (4 more) Less
Language :
English
Title :
Abstract 2993: Unmutated tumor antigens are abundant and contribute to tumor control in melanoma
Publication date :
04 April 2023
Event name :
AACR annual meeting 2023
Event organizer :
AACR
Event date :
April 14-19
Audience :
International
Journal title :
Cancer Research
ISSN :
0008-5472
eISSN :
1538-7445
Publisher :
American Association for Cancer Research (AACR)
Volume :
83
Issue :
7_Supplement
Pages :
2993-2993
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 19 May 2023

Statistics


Number of views
16 (0 by ULiège)
Number of downloads
0 (0 by ULiège)

OpenCitations
 
0
OpenAlex citations
 
0

Bibliography


Similar publications



Contact ORBi